NEW YORK (GenomeWeb News) – Finnish biotech firm Biohit today announced a distribution agreement with Hefei Medicine covering China.

The deal covers the distribution and marketing of Biohit's diagnostic products. Financial and other terms of the deal were not disclosed.

Among the products covered by today's announcement are Biohit's GastroPanel blood-based biomarker tests. The tests are for screening and diagnosing Helicobacter pylori.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.

In Science this week: the Human Silencing Hub protein complex, and more.